DOW JONES21,052.53-360.91 -1.69%
S&P 5002,488.65-38.25 -1.51%
NASDAQ7,373.08-114.23 -1.53%

H.C. Wainwright Maintains Neutral on Aimmune Therapeutics, Lowers Price Target to $30

H.C. Wainwright maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and lowers the price target from $33 to $30.

Benzinga · 02/28/2020 12:12

H.C. Wainwright maintains Aimmune Therapeutics (NASDAQ:AIMT) with a Neutral and lowers the price target from $33 to $30.